Q2 Earnings Estimate for Liquidia Issued By Lifesci Capital

Liquidia Co. (NASDAQ:LQDA) – Analysts at Lifesci Capital issued their Q2 2025 earnings per share estimates for Liquidia in a research note issued to investors on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia’s Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.41) EPS.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

Several other equities research analysts have also recently weighed in on the company. Scotiabank increased their price objective on Liquidia from $30.00 to $34.00 and gave the stock a “sector outperform” rating in a report on Thursday, March 20th. Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, March 20th. Finally, Needham & Company LLC lifted their target price on shares of Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $26.63.

Liquidia Price Performance

NASDAQ LQDA opened at $15.66 on Monday. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.92. The stock has a market capitalization of $1.34 billion, a PE ratio of -9.61 and a beta of 0.07. The business’s 50-day moving average is $14.87 and its 200 day moving average is $12.27.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently made changes to their positions in the company. Corebridge Financial Inc. lifted its position in Liquidia by 2.3% in the 4th quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock valued at $371,000 after acquiring an additional 694 shares in the last quarter. Catalina Capital Group LLC increased its holdings in Liquidia by 6.5% in the 4th quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock worth $215,000 after buying an additional 1,125 shares in the last quarter. Cetera Investment Advisers increased its holdings in Liquidia by 4.3% in the 4th quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock worth $367,000 after buying an additional 1,277 shares in the last quarter. Summit Investment Advisors Inc. raised its position in Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after buying an additional 1,719 shares during the last quarter. Finally, Sigma Planning Corp lifted its stake in Liquidia by 3.4% during the 4th quarter. Sigma Planning Corp now owns 65,210 shares of the company’s stock valued at $767,000 after acquiring an additional 2,115 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Activity at Liquidia

In related news, insider Rajeev Saggar sold 2,445 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the transaction, the insider now owns 267,943 shares in the company, valued at $3,483,259. The trade was a 0.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Russell Schundler sold 16,393 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $193,109.54. Following the sale, the general counsel now owns 573,478 shares of the company’s stock, valued at approximately $6,755,570.84. This represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock valued at $843,326 in the last three months. Company insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).